Comments on: Arqule’s Theater of the Absurd http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/ Biotech stock reviews Tue, 07 Sep 2010 01:45:45 +0000 http://wordpress.org/?v=2.3.1 By: Active Trader http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-435 Active Trader Mon, 15 Dec 2008 16:12:22 +0000 http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-435 We could see a 30-40% recovery of ARQL share by next July. We could see a 30-40% recovery of ARQL share by next July.

]]> By: StockBlogHub http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-434 StockBlogHub Wed, 10 Dec 2008 00:04:22 +0000 http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-434 Ohad, Do you want to sell your financial articles? Hello fellow blogger, we could not find your email, so we hope this comment reaches you. StockBlogHub wants quality investing bloggers to join us for: revenue sharing, and proven traffic. We can process posts from your RSS feed or you can post manually. You earn money, get traffic, and control your content - Your content remains unchanged. We are assembling a focused group of content providers to execute a deal with major financial publishers for significant syndication. Please visit now to learn who we are and how we do it: http://www.stockbloghub.com/contacting-publishers Ohad,

Do you want to sell your financial articles?

Hello fellow blogger, we could not find your email, so we hope this comment reaches you. StockBlogHub wants quality investing bloggers to join us for: revenue sharing, and proven traffic. We can process posts from your RSS feed or you can post manually. You earn money, get traffic, and control your content - Your content remains unchanged. We are assembling a focused group of content providers to execute a deal with major financial publishers for significant syndication. Please visit now to learn who we are and how we do it: http://www.stockbloghub.com/contacting-publishers

]]> By: Jenny R. http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-432 Jenny R. Sun, 07 Dec 2008 23:58:15 +0000 http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-432 I am a new blogger which has given me appreciation of what others do with their blogs. I just wanted to say good work and although our sites are not really related if you want to swap blogrole links I would be interested. I am a new blogger which has given me appreciation of what others do with their blogs. I just wanted to say good work and although our sites are not really related if you want to swap blogrole links I would be interested.

]]> By: Justin MacArthur http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-431 Justin MacArthur Wed, 03 Dec 2008 04:17:00 +0000 http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-431 Hey Ben, It's great to see those companies expanding with new biotech methods! The clinical data that ARQL generated is quite exciting and I hope the company can continue its growth. Commission Blueprint Editor Hey Ben,

It’s great to see those companies expanding with new biotech methods! The clinical data that ARQL generated is quite exciting and I hope the company can continue its growth.

Commission Blueprint Editor

]]> By: Ohad Hammer http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-428 Ohad Hammer Sat, 29 Nov 2008 11:32:18 +0000 http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-428 Hi Ben I am now in india with limited internet access, so unless I am missing some recent developments, I think that with the two partnership deals in place and the clinical data ARQ197 has generated to date, ARQL should be a 5$ stock. With respect to MITI, it remains to be seen whether they will present updated data from the NHL trial (higher doses and duration of responses). The ALL data seems even more exciting, providing that switching patients from minimal residual disease to negative can lead to better survival after stem cell transplant. Ohad Hi Ben

I am now in india with limited internet access, so unless I am missing some recent developments, I think that with the two partnership deals in place and the clinical data ARQ197 has generated to date, ARQL should be a 5$ stock.

With respect to MITI, it remains to be seen whether they will present updated data from the NHL trial (higher doses and duration of responses). The ALL data seems even more exciting, providing that switching patients from minimal residual disease to negative can lead to better survival after stem cell transplant.

Ohad

]]> By: Ben H. http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-426 Ben H. Wed, 26 Nov 2008 13:52:01 +0000 http://www.hammerstockblog.com/arqule%e2%80%99s-theater-of-the-absurd/#comment-426 Hi Ohad Do you think we could see another 20-30% lift if markets are calm? btw, being one of the first who started covering MITI, Can you write your thoughts on the company going into ASH? Thanks a lot, Ben Hi Ohad

Do you think we could see another 20-30% lift if markets are calm?

btw, being one of the first who started covering MITI, Can you write your thoughts on the company going into ASH?

Thanks a lot,
Ben

]]>